Integra LifeSciences Q3 Adj. EPS Meets Street View, Revenue Misses Forecast; Tightens FY Revenue Outlook

Integra LifeSciences Holdings (IART) reported pre-market Wednesday Q3 adjusted earnings of $0.59 per share, in line with the analyst consensus and higher than last year’s adjusted earnings of $0.45 per share.

The surgical instruments manufacturer generated revenue of $365.9 million, which is up from $278.8 million in the same quarter last year. Analysts polled by CapIQ were expecting revenue of $367.9 million.

The company also said that it is reiterating its FY2018 adjusted earnings per share guidance range of $2.36 to $2.42. It now expects full-year revenue of $1.47 billion. The previous outlook was $1.47 billion to $1.49 billion. Analysts are expecting full-year adjusted EPS of $2.40 and sales of $1.49 billion.